Ecabet Sodium

CAS No. 86408-72-2

Ecabet Sodium( —— )

Catalog No. M16263 CAS No. 86408-72-2

Ecabet sodium: a potential new agent in the management of distal colitis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 39 Get Quote
50MG 87 Get Quote
100MG 129 Get Quote
200MG 188 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ecabet Sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Ecabet sodium: a potential new agent in the management of distal colitis.
  • Description
    Ecabet sodium: a potential new agent in the management of distal colitis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    86408-72-2
  • Formula Weight
    402.48
  • Molecular Formula
    C20H27NaO5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)S(=O)(=O)[O-].[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lawrance IC. J Gastroenterol Hepatol. 2010 Jul;25(7):1182-4.
molnova catalog
related products
  • 7-Hydroxyaristolochi...

    7-Hydroxyaristolochic acid A is a natural product from Aristolochia debilis Sieb.

  • 24-Norursodeoxycholi...

    24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.?

  • Tranilast

    A compound that exhibits anti-inflammatory and immunomodulatory effects by inhibiting lipid mediator and cytokine release from inflammatory cells and interfering with PDGF- and TGF-β1-induced proliferation and migration of vascular medial smooth muscle cells.